Parkinson’s Patients May Be Harmed by Novel Treatment

Posted on March 21st, 2013 by Logan Lafferty

The study examined the progression of 1,098 patients who had their DNA sequenced at the Mayo Clinic and were contacted as many as 15 years later to determine how they were faring…Alnylam, based in Cambridge, Massachusetts, licensed alpha- synuclein technology from the Mayo Clinic and is developing a product that would be delivered directly into the brains of patients.

Additional Coverage: Bloomberg

 

Bloomberg Businessweek by Michelle Fay Cortez

Tags: Alnylam, Bloomberg Businessweek, DNA sequence, Neurology, new technology, parkinson's disease, Research, Technology

You must be logged-in to the site to post a comment.

Contact Us · Privacy Policy